未登录

S

Sarah Untch

university of oklahoma - norman

H指数:4

被引数:172

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

EVALUATION OF PAXALISIB IN GBM AGILE PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

PAXALISIB在新诊断和复发胶质母细胞瘤的GBM敏捷3期注册平台试验中的评估

IF13.4

2024-11-110

PRE

Mellinghoff, Ingo K.; Cloughesy, Timothy; Alexander, Brian; Berry, Donald A.; Buxton, Meredith; Cavenee, Webster; Colman, Howard; de Groot, John; Ellingson, Benjamin M.; Gordon, Gary B.; Lassman, Andrew B.; Lim, Michael; Khasraw, Mustafa; Perry, James; Sulman, Erik P.; Weller, Michael; Wen, Patrick; Yung, W. K. Alfred; Berry, Nicholas; Graves, Todd; Detry, Michelle; Hyddmark, E. M. Viktoria; Johnsson, Adam; Kling, Heather; Mcglothlin, Anna; Powell, Ashley; Untch, Sarah; Aquilanti, Elisa; Blondin, Nicholas; Boulmay, Brian; de la Fuente, Macarena; Drappatz, Jan; Jordan, Justin; Kaley, Thomas J.; Lobbous, Mina; Mikkelsen, Tom; Newton, Herbert; Owen, Scott; Peters, Katherine; Schiff, David; Sherman, Wendy; Weathers, Shiao-Pei; Youssef, Michael; Friend, John; Lee, Eudocia

UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

GBM AGILE的更新: 一项全球2/3期适应性平台试验，用于评估新诊断和复发性胶质母细胞瘤的多种治疗方案

IF13.4

2024-11-110

PRE

Lassman, Andrew; Alexander, Brian; Berry, Donald; Berry, Nicholas; Buxton, Meredith; Colman, Howard; Gan, Hui; de Groot, John; de la Fuente, Macarena; Drappatz, Jan; Ducray, Francois; Ellingson, Benjamin; Gordon, Gary; Hyddmark, Emma; Johnson, Adam; Khasraw, Mustafa; Lee, Eudocia; Lim, Michael; Mcglothlin, Anna; Mellinghoff, Ingo; Mikkelsen, Tom; Nghiemphu, Phioanh; Perry, James; Powell, Ashley; Sulman, Erik; Tanner, Krik; Untch, Sarah; Weller, Michael; Wen, Patrick; Wick, Antje; Yung, Alfred; Cloughesy, Timothy

The FLEX real world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer

CANCER RESEARCH

IF16.6

2020-08-150

PRE

Treatment recommendations in ER plus patients ≤ 50 years: Comparison of the 21-gene assay and 70-gene signature in the PROMIS study

CANCER RESEARCH

IF16.6

2020-02-150

PRE

The FLEX real world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer

CANCER RESEARCH

IF16.6

2020-02-150

PRE

Different MammaPrint and BluePrint molecular profiles and clinical-pathological features of early stage breast cancer in Chinese patients in the United States and Hong Kong

CANCER RESEARCH

IF16.6

2020-02-150

PRE

Racial disparities in breast cancer: Identifying predisposing clinical and molecular features associated with African American patients

CANCER RESEARCH

IF16.6

2020-02-150

PRE

MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial

IF3.4

2020-01-3146

OAAI

MammaPrint identifies 46% of patients, age ≤50 years with oncotype RS 18-30, as low risk and safe to forgo chemotherapy

CANCER RESEARCH

IF16.6

2019-02-150

PRE

MammaPrint, BluePrint, and full-genome data linked with clinical data to evaluate new gene expression profiles (FLEX)

CANCER RESEARCH

IF16.6

2019-02-150

PRE

Metabolic syndrome increases risk of recurrence and impacts immune pathways in invasive lobular carcinoma

CANCER RESEARCH

IF16.6

2019-02-150

PRE

Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

ANNALS OF SURGICAL ONCOLOGY

IF3.5

2017-04-2637

PREAI

MINT trial yields MammaPrint High1/High2 risk classes associated with significant differences in pCR and receptor subtype

CANCER RESEARCH

IF16.6

2017-02-151

PRE

Measuring the impact of MammaPrint on treatment in breast cancer patients: A prospective registry (IMPACt)

CANCER RESEARCH

IF16.6

2017-02-150

PRE

Three distinct HER2 subtypes identified by BluePrint 80-gene functional subtyping predict treatment -specific response in the prospective neo-adjuvant NBRST registry

CANCER RESEARCH

IF16.6

2016-02-150

PRE

One-third of HER2 positive patients have 80-gene luminal subtype that is resistant to chemo-trastuzumab but sensitive to chemo-trastuzumab-pertuzumab: Critical implications for the adjuvant setting from the NBRST phase 4 neoadjuvant study

CANCER RESEARCH

IF16.6

2016-02-150

PRE

Pertuzumab overcomes chemotherapy/trastuzumab resistance in ER+/Her2+tumors classified as luminal functional subtype by the 80-gene BluePrint assay in the prospective neo-adjuvant breast registry symphony trial (NBRST)

CANCER RESEARCH

IF16.6

2016-02-150

PRE

Functional subtyping with BluePrint 80-gene profile identifies two distinct triple positive subtypes with and without trastuzumab/chemo-sensitivity: Implications for treatment from the NBRST registry

CANCER RESEARCH

IF16.6

2015-05-010

PRE

PROMIS: PRospective study Of MammaPrint in breast cancer patients with an Intermediate recurrence Score (PROMIS)

CANCER RESEARCH

IF16.6

2015-05-010

PRE

MINT I: Multi-Institutional Neo-adjuvant Therapy, MammaPrint Project I

CANCER RESEARCH

IF16.6

2015-05-010

PRE